Contemporary role of avelumab first-line maintenance in advanced urothelial carcinoma with consideration of the JAVELIN Bladder 100 comprehensive clinical subgroup analyses

Kevin K. Zarrabi; Benjamin Miron; Daniel M. Geynisman

doi:10.21037/tau-23-576

Contemporary role of avelumab first-line maintenance in advanced urothelial carcinoma with consideration of the JAVELIN Bladder 100 comprehensive clinical subgroup analyses

Kevin K. Zarrabi, Benjamin Miron, Daniel M. Geynisman

Thomas Jefferson University

Research output: Contribution to journal › Editorial

Original language	English
Pages (from-to)	405-466
Number of pages	62
Journal	Translational Andrology and Urology
Volume	13
Issue number	3
DOIs	https://doi.org/10.21037/tau-23-576
State	Published - Mar 31 2024

Keywords

Urothelial carcinoma (UC)
enfortumab vedotin (EV)
immunotherapy

Access to Document

10.21037/tau-23-576

Cite this

@article{4ee983910fb44cceb6af9a8d4d52ce69,

title = "Contemporary role of avelumab first-line maintenance in advanced urothelial carcinoma with consideration of the JAVELIN Bladder 100 comprehensive clinical subgroup analyses",

keywords = "Urothelial carcinoma (UC), enfortumab vedotin (EV), immunotherapy",

author = "Zarrabi, {Kevin K.} and Benjamin Miron and Geynisman, {Daniel M.}",

year = "2024",

month = mar,

day = "31",

doi = "10.21037/tau-23-576",

language = "English",

volume = "13",

pages = "405--466",

journal = "Translational Andrology and Urology",

issn = "2223-4683",

publisher = "AME Publishing Company",

number = "3",

}

TY - JOUR

T1 - Contemporary role of avelumab first-line maintenance in advanced urothelial carcinoma with consideration of the JAVELIN Bladder 100 comprehensive clinical subgroup analyses

AU - Zarrabi, Kevin K.

AU - Miron, Benjamin

AU - Geynisman, Daniel M.

PY - 2024/3/31

Y1 - 2024/3/31

KW - Urothelial carcinoma (UC)

KW - enfortumab vedotin (EV)

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85191015404&partnerID=8YFLogxK

U2 - 10.21037/tau-23-576

DO - 10.21037/tau-23-576

M3 - Editorial

C2 - 38590958

AN - SCOPUS:85191015404

SN - 2223-4683

VL - 13

SP - 405

EP - 466

JO - Translational Andrology and Urology

JF - Translational Andrology and Urology

IS - 3

ER -

Contemporary role of avelumab first-line maintenance in advanced urothelial carcinoma with consideration of the JAVELIN Bladder 100 comprehensive clinical subgroup analyses

Keywords

Access to Document

Other files and links

Fingerprint

Cite this